James B. Breitmeyer M.D., Ph.D.

Dr. Breitmeyer has served as a member of our board of directors since March 2014. He currently serves as President, CEO and Director of Oncternal Therapeutics, Inc. a clinical-stage oncology biotech developing first-in-class therapies for both rare and common malignancies. He was most recently President of Bavarian Nordic, Inc. in the United States and Executive Vice President of Bavarian A/S, a multinational corporation headquartered in Denmark. He previously served as the acting Chief Medical Officer of Zogenix Inc. in an advisory capacity, the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly-owned subsidiary of Eli Lilly and Co. Dr. Breitmeyer has also served as President and Chief Executive Officer of the Harvard Clinical Research Institute and held a variety of positions at Serono Laboratories Inc. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer holds a BA in Chemistry from the University of California, Santa Cruz and an M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology.